topotecan has been researched along with sirolimus in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 10 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bubley, GJ; Jones, GB; Torregrossa, J | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Belozerov, VE; Van Meir, EG | 1 |
| Dai, Y; Gupta, A; Hebert, MF; Mao, Q; Ross, DD; Thummel, KE; Unadkat, JD; Vethanayagam, RR | 1 |
| Argentieri, D; Falotico, R; Parry, TJ; Siekierka, J; Tallarida, RJ; Thyagarajan, R | 1 |
| Geng, MY; Li, J; Wang, JJ | 1 |
| Fleming, GF; Temkin, SM; Yamada, SD | 1 |
| Kurzrock, R; Subbiah, V; Trent, JC | 1 |
| Bowyer, C; Forster, RE; Lewis, AL; Lloyd, AW; Macfarlane, W; Phillips, GJ; Tang, Y | 1 |
| Abu-Khalaf, MM; Acevedo-Gadea, C; Azodi, M; Higgins, SA; Ratner, E; Rutherford, T; Santin, AD; Schwartz, PE; Silasi, DA; Urva, S | 1 |
| Hamasaki, T; Hisamatsu, T; Kawano, M; Kimura, T; Kishimoto, T; Mabuchi, S; Matsumoto, Y; Sasano, T; Sawada, K; Takahashi, K; Takahashi, R; Takahashi, T | 1 |
| Matsumoto, K; Onda, T; Yaegashi, N | 1 |
| Gad, Y; Helgason, T; Hong, DS; Jain, RK; Kurzrock, R; Naing, A; Shi, NY; Wheler, J | 1 |
| Allen, S; DuBois, SG; Gustafson, WC; Hollinger, F; Karski, EE; Long-Boyle, JR; Matthay, KK; Nasholm, NM; Shiboski, S; Vo, KT | 1 |
| Altman, JK; Broun, ER; Carroll, MP; Karp, JE; Kaufmann, SH; Ketterling, RP; Lazarus, HM; Litzow, MR; Luger, SM; Paietta, EM; Pratz, KW; Rowe, JM; Rybka, WB; Tallman, MS; Tun, HW; Wang, XV; Zhang, Y | 1 |
4 review(s) available for topotecan and sirolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Hypoxia inducible factor-1: a novel target for cancer therapy.
Topics: Benzopyrans; Cell Hypoxia; Heterocyclic Compounds, 4 or More Rings; Humans; Hypoxia-Inducible Factor 1; Microtubules; Models, Biological; Mustard Compounds; Neoplasms; Phenylpropionates; Phosphoinositide-3 Kinase Inhibitors; Signal Transduction; Sirolimus; Topotecan; Tubulin Modulators | 2005 |
[Recent progress in the study on antitumor drugs targeting hypoxia-inducible factor-1].
Topics: Amphotericin B; Animals; Antineoplastic Agents; Echinomycin; Humans; Hypoxia-Inducible Factor 1; Indazoles; Sirolimus; Topotecan; Transcription, Genetic | 2008 |
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids | 2015 |
5 trial(s) available for topotecan and sirolimus
| Article | Year |
|---|---|
A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genital Neoplasms, Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Sirolimus; Topotecan | 2010 |
Phase I clinical trial of the mammalian target of rapamycin inhibitor everolimus in combination with oral topotecan for recurrent and advanced endometrial cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Endometrial Neoplasms; Everolimus; Female; Humans; Immunosuppressive Agents; Middle Aged; Neoplasm Recurrence, Local; Sirolimus; Topoisomerase I Inhibitors; Topotecan; TOR Serine-Threonine Kinases | 2014 |
Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Computer Simulation; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Models, Biological; Molecular Targeted Therapy; Neoplasms; S Phase Cell Cycle Checkpoints; Sirolimus; Texas; Time Factors; Topotecan; Treatment Outcome; Young Adult | 2015 |
Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Female; Humans; Male; Neoplasm Recurrence, Local; Neoplasms; Sirolimus; Topotecan; Young Adult | 2017 |
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Flavonoids; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Recurrence; Remission Induction; Salvage Therapy; Sirolimus; Topotecan; Tumor Lysis Syndrome | 2019 |
7 other study(ies) available for topotecan and sirolimus
| Article | Year |
|---|---|
Microwave expedited synthesis of 5-aminocamptothecin analogs: Inhibitors of hypoxia inducible factor HIF-1alpha.
Topics: Camptothecin; Cell Line; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Microwaves; Molecular Structure; Structure-Activity Relationship | 2006 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cyclosporine; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Immunosuppressive Agents; Mitoxantrone; Neoplasm Proteins; Sirolimus; Substrate Specificity; Tacrolimus; Topotecan | 2006 |
Effects of drug combinations on smooth muscle cell proliferation: an isobolographic analysis.
Topics: Algorithms; Cell Proliferation; Cell Survival; Cells, Cultured; Cladribine; Coronary Vessels; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Growth Inhibitors; Humans; Myocytes, Smooth Muscle; Sirolimus; Topotecan | 2006 |
Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Intracellular Signaling Peptides and Proteins; Middle Aged; Perivascular Epithelioid Cell Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Retroperitoneal Neoplasms; Sirolimus; Topotecan; TOR Serine-Threonine Kinases; Treatment Failure | 2010 |
Development of a combination drug-eluting bead: towards enhanced efficacy for locoregional tumour therapies.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Doxorubicin; Humans; Irinotecan; Liver Neoplasms; Mice; Mice, Nude; Pancreatic Neoplasms; Prostheses and Implants; Sirolimus; Topotecan; Xenograft Model Antitumor Assays | 2012 |
Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Proliferation; Cisplatin; Dioxoles; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Sirolimus; Tetrahydroisoquinolines; Topotecan; Trabectedin; Tumor Cells, Cultured | 2014 |